PR Newswire
11 Nov 2022, 17:30 GMT+10
![]() |
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that Dr Christian Behrenbruch, Group CEO and Managing Director, will be presenting at the Jefferies London Healthcare Conference 2022.
The presentation will take place on Thursday 17 November from 3:15 - 3:45pm GMT (10:15 - 10:45am EST / 2:15 - 2:45am AEDT, 18 Nov).
A live webcast of the presentation will be available at the following link: https://wsw.com/webcast/jeff255/tlx/1728648
The webcast will be accessible on demand on the Telix website following the event.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),[1] and by the Australian Therapeutic Goods Administration (TGA),[2] and by Health Canada.[3]
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: [email protected]
[1] ASX disclosure 20 December 2021.
[2] ASX disclosure 2 November 2021.
[3] ASX disclosure 14 October 2022.
This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer.
Legal Notices
This announcement is not intended as promotion or advertising directed to any healthcare professional or other audience in any country worldwide (including Australia, United States and the United Kingdom). This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates - all rights reserved.
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationLOS ANGELES, California: The Trump administration is once again challenging California's high-speed rail project, with federal transportation...
LUBBOCK, Texas: The Republican attorney general of Texas, Ken Paxton, wants the NCAA to strengthen its transgender athlete policy by...
When the Eaton Fire began on January 7, 2025, in Altadena, California, it blazed through residential neighborhoods, destroying thousands...
HANCEVILLE, Alabama: A grand jury has recommended shutting down a small police department in Alabama due to widespread corruption after...
CLARKSDALE, Mississippi: A judge in Mississippi has ordered a newspaper to take down an editorial that criticized the mayor and city...
JERUSALEM, Israel - Two bills that have passed a preliminary reading in the Knesset have raised concerns among civil society groups...
TOKYO, Japan: Foxconn has approached Honda Motor with a proposal to form a partnership, aiming to establish a broader collaboration...
NEW YORK, New York - There was a mix of gains and losses in the United States on Tuesday with tech stocks selling off, and industrials...
BERLIN, Germany: Audi is moving forward with plans to expand production in North America, and CEO Gernot Doellner said a decision on...
TOKYO, Japan: The Bank of Japan is expected to raise interest rates at least once more this year, likely in the third quarter, bringing...
NEW YORK, New York - U.S. stock markets closed lower on Monday, with the major indexes showing mixed performances as investors digested...
BLAGNAC, France: Airbus has set a target of delivering around 820 commercial jets in 2025, marking a seven percent increase from the...